PharmaFocus Today – Page 36 – media

34 million patients no longer rely on imported drugs

In China, the number of people suffering from attention deficit hyperactivity disorder (ADHD) has exceeded 34 million. For a long time, the clinical treatment of this group has been heavily reliant on imported drugs. With the launch of the first generic drug by Lifang Pharmaceutical, the approval of multiple dosage forms of improved new drugs by Youer Pharmaceutical, and the successful approval of innovative compound preparations by Aikebaifa, several domestically produced ADHD treatment drugs have been launched, and the reliance on imported drugs is gradually being broken. In the ADHD sector, a breakthrough battle for domestic substitution and upgrading has officially begun. 01 Market potential awaits release Attention deficit hyperactivity disorder (ADHD) is a common chronic neurodevelopmental disorder characterized by disproportionate attention deficits and hyperactivity, manifesting as poor concentration, impulsivity, hyperactivity, and learning difficulties. According to the “Pediatric Expert Consensus on Early Identification, Standardized Diagnosis and Treatment of Attention Deficit ...
- Source: drugdu
- 287
- February 25, 2026
How far can GLP-1 go in the weight loss race?

At the start of 2026, a business development (BD) deal between CSPC Pharmaceutical Group and AstraZeneca set a new record for the highest amount of foreign licensing for Chinese biopharmaceutical companies, with a potential value of over US$18.5 billion. This record-breaking business development deal has once again propelled the research and development of weight-loss drugs to a new level . According to the agreement, AstraZeneca has acquired the global exclusive rights to CSPC Pharmaceutical Group’s once-monthly injectable weight management product portfolio outside of Greater China, including one clinical-ready project SYH2082, three preclinical projects, and four new collaborative projects based on CSPC Pharmaceutical Group’s platform. It is worth mentioning that SYH2082 is a GLP1R/GIPR agonist, which means that GLP-1 will continue to be popular in the weight loss field. 01 Blood sugar reduction has been unknown for many years One day of weight loss produced a medicine king With the release ...
- Source: drugdu
- 154
- February 25, 2026
Aohong Pharmaceutical | Drug registration application for Motomidyl Hydrochloride Injection accepted by CDE

Recently, the National Medical Products Administration accepted the drug registration application of Motomidate Hydrochloride Injection (Project Code: ET-26, Application Registration Category: Class 1 Chemical Drug; hereinafter referred to as “the new drug”) by Jinzhou Aohong Pharmaceutical Co., Ltd., a subsidiary of Fosun Pharma (stock code: 600196.SH; 02196.HK). The proposed indication for this application is for anesthesia induction and short-term surgical anesthesia. This new drug is a Class 1 new drug for intravenous general anesthesia and was included in the “Major New Drug Development” science and technology major project in 2014.According to the latest data from IQVIA CHPA1 , in 2024, sales of similar drugs (such as etomidate) used for anesthesia induction and short-term surgical anesthesia in mainland China (excluding Hong Kong, Macao and Taiwan) amounted to approximately RMB 4.238 billion.As a wholly-owned subsidiary of Fosun Pharma, Aohong Pharmaceutical has always regarded innovation as the core driving force for its sustainable ...
- Source: drugdu
- 131
- February 24, 2026
Hansoh Pharmaceutical’s blockbuster new drug has been approved for marketing in the European Union!

Just now, Hansoh Pharmaceutical announced that its innovative drug, Ametinib Mesylate Tablets (Chinese trade name: Ameile® , overseas trade name: Aumseqa® ) , has been officially approved by the European Commission ( EC ) for marketing in the European Union for the treatment of: First-line treatment for adult patients with advanced non-small cell lung cancer ( NSCLC ) with epidermal growth factor receptor ( EGFR ) exon 19 deletion or exon 21 ( L858R ) substitution mutation ; Treatment of adult patients with advanced EGFR T790M mutation-positive NSCLC . This approval came after the European Medicines Agency ( EMA ) Committee for Medicinal Products for Human Use ( CHMP ) issued a positive opinion. Ametinib thus becomes the first Chinese-developed EGFR-TKI drug to receive EU approval, marking another breakthrough for domestically produced targeted innovative lung cancer drugs in the European market. Ametinib mesylate tablets (Aumseqa® ) are China’s first original ...
- Source: drugdu
- 189
- February 24, 2026
Jinsai Pharmaceutical’s new drug officially approved for clinical trials to improve micropenis in children!

On February 24, the CDE website showed that GenSci141 ointment , submitted by Jinsai Pharmaceutical , was approved for clinical trials. It is indicated for improving micropenis in children caused by hypergonadotropic hypogonadism, 5α-reductase 2 deficiency, congenital adrenal hyperplasia with reduced androgen synthesis, and idiopathic causes. The registration categories are 2.2 and 2.4. GenSci141 ointment is a dihydrotestosterone ointment developed by Jinsai Pharmaceutical . It mainly works by paracrine secretion within target tissues, targeting and promoting penile tissue growth and development. According to publicly available information, there are currently no approved drugs worldwide specifically for micropenis in children, indicating a significant unmet clinical need. If successful, GenSci141 ointment could become the world’s first drug specifically for micropenis in children. https://mp.weixin.qq.com/s/lKYLBl1EyMWSjlHehOE0Kw
- Source: drugdu
- 172
- February 24, 2026
Frontier Biotechnologies Enters Global Licensing Collaboration with GlaxoSmithKline for Small Nucleic Acid Drugs

Recently, Frontier Biotechnologies (Nanjing) Co., Ltd. (hereinafter referred to as “Frontier Biotechnologies” or the “Company”) has officially entered into an exclusive license agreement with GlaxoSmithKline (hereinafter referred to as “GSK”), a global biopharmaceutical company. Pursuant to the agreement, GSK will obtain the global exclusive rights to develop, manufacture and commercialize two small interfering RNA (siRNA) pipeline products. One of the drug candidates has entered the Investigational New Drug (IND) application stage, and the other is a preclinical candidate. This agreement demonstrates the Company’s expertise in the early-stage discovery and development of siRNA drugs, representing an important milestone in advancing the Company’s global development strategy. Under the agreement, the Company will receive an upfront payment of USD 40 million, and up to an aggregate of USD 963 million in development, regulatory and commercialization milestone payments across the two programs, as well as tiered royalties on the global net sales of both ...
- Source: drugdu
- 198
- February 24, 2026
Rising Star in Oral Weight Loss! Hengrui’s GLP 1R/GIPR Agonist Succeeds in Phase II Study

On February 10, 2026, Hengrui Pharmaceutical and Kailera Therapeutics (US) jointly announced positive top-line results from a Phase II clinical trial (NCT06841445) of Remputeptide Tablets (HRS9531), their investigational GLP 1/GIP dual receptor agonist, in Chinese adults with obesity. Data showed that at Week 26, mean body weight reduction in the highest dose group reached 12.1%, with no weight loss plateau observed. Up to 38.6% of participants achieved at least 15% weight loss, while the incidence of gastrointestinal adverse events was maintained at a low level. This breakthrough marks important progress in the global development of oral multi target weight loss drugs. With its convenient once daily oral administration and robust efficacy data, Remputeptide Tablets is expected to offer a new therapeutic option for patients with obesity that may surpass injectable formulations. It also adds a key competitive asset to Hengrui’s global strategic layout in metabolic diseases. 1 Remputeptide: Dual pathway ...
- Source: drugdu
- 488
- February 13, 2026
adjuvant therapy for breast cancer

On February 12, Daiichi Sankyo announced that its injectable detrastuzumab (Uroder®, DS-8201a, T-DXd) has been approved for inclusion in the Breakthrough Therapy Designation (BTD) program by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment of adult patients with HER2-positive breast cancer who still have residual invasive lesions after neoadjuvant anti-HER2 therapy. Detrastuzumab was developed by Daiichi Sankyo and co-developed by Daiichi Sankyo and AstraZeneca.A jointly developed HER2-targeting antibody-drug conjugate (ADC). https://finance.eastmoney.com/a/202602123648930874.html
- Source: drugdu
- 349
- February 13, 2026
The approval of telpopril monotherapy for type 2 diabetes has driven an upgrade in the management paradigm

　　According to this newspaper, in current clinical practice, the treatment of type 2 diabetes often relies heavily on the traditional approach of “gradually increasing medication.” Many patients only enter a more potent treatment phase after their blood sugar has been poorly controlled for a long time and the risk of complications has gradually accumulated. 　　However, in recent years, discussions surrounding early diabetes management have been undergoing a significant shift. A growing body of research suggests that the choice of treatment starting point not only affects short-term glycemic control but also profoundly relates to patients’ long-term complication risk and overall prognosis. Clinical management strategies for type 2 diabetes are shifting from a “late-stage reinforcement” approach to a new paradigm of “intervention at the starting point.” 　　February 11th, ReiThe innovative dual-target drug Mufengda® (Telborpeptide Injection) has been approved by the China National Medical Products Administration for monotherapy in adults with type 2 ...
- Source: drugdu
- 170
- February 13, 2026
Oral insulin launch fails; China Resources Pharmaceutical plans to sell Tianmai Biotechnology

On February 9, China Resources Pharmaceutical (03320.HK) issued an announcement on the Hong Kong Stock Exchange, stating that its wholly-owned subsidiary, China Resources Pharmaceutical Investment Co., Ltd., plans to sell its 17.87% stake in Hefei Tianmai Biotechnology Development Co., Ltd. (hereinafter referred to as “Tianmai Biotechnology”) through a public listing on the Shanghai United Assets and Equity Exchange, with a listing price of RMB 1.42 billion. Looking back at the history of cooperation between China Resources Pharmaceutical and Tianmai Biotechnology, their partnership began in 2016, when the number of diabetes patients in China continued to rise, leading to a surge in demand for insulin as a core treatment drug. At the same time, China Resources Pharmaceutical was also seeking to expand into the biopharmaceutical field. Against this backdrop, China Resources Pharmaceutical signed a strategic agreement in December 2016 to acquire a 20% stake in Tianmai Biotechnology, thus officially entering the ...
- Source: drugdu
- 163
- February 13, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.